Compounds › Combinations

Advanced Recomp

Retatrutide + CJC-1295 without DAC + ipamorelin

Not approvedCombinations

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Specific caution for this compound: Three unapproved compounds at the same time. If something goes wrong, there is no way to know which of the three it was.

Summary

Combines three peptides in a single protocol: retatrutide, CJC-1295 (without DAC) and ipamorelin. The stated logic is direct — lose fat fast with retatrutide and try to preserve lean mass with the CJC-1295 + ipamorelin pair. It is the most loaded combination in this reference, with three unapproved compounds at the same time.

Quick reference

Reconstitution: Separate vials for each compound. Pre-mixed CJC/Ipa vials cut it from three reconstitutions to two.
Schedule: 1 weekly SC application of retatrutide. 1–2 daily SC applications of CJC/Ipa, before bed and fasted.
Measure: U-100 syringe. 100 mcg of CJC or ipamorelin in a 2,000 mcg/mL solution = 5 units.
Status: Not approved. WADA prohibits CJC-1295 and ipamorelin in tested sport.

Retatrutide Titration Phases

Phase	Weeks	Weekly Dose	Notes
Initiation	1-4	2 mg	Starting dose; assess GI tolerance.
Early escalation	5-8	4 mg	Increase by 2 mg every 4 weeks.
Mid escalation	9-12	6 mg	Watch GI side effects; slow if needed.
Therapeutic range	13-16	9 mg	Skip to 9 mg or hold at 6 mg by tolerance.
Maximum dose	17-20+	12 mg	Highest dose studied; not all users need it.

Retatrutide Titration (Same in Both Formats)

Phase	Weeks	Weekly Dose	Notes
Initiation	1-4	2 mg	Start; assess GI tolerance.
Early escalation	5-8	4 mg	Step up every 4 weeks.
Mid escalation	9-12	6 mg	Watch GI; slow if needed.
Therapeutic range	13-16	9 mg	Step to 9 mg or hold at 6 mg.
Maximum dose	17-20+	12 mg	Highest dose studied.

Cycle Guidelines

Approach	Duration	Off period	Best for
Standard cycle	12-16 weeks	4 weeks off CJC/Ipa; retatrutide can continue	Moderate recomp; first-time users
Extended cycle	16-24 weeks	4-6 weeks off CJC/Ipa	Aggressive recomp; experienced users
Continuous reta + cycled GH	Retatrutide ongoing; CJC/Ipa 12 on / 4 off	4-week CJC/Ipa breaks	Long-term body composition management

Retatrutide Reconstitution

Vial size	BAC water added	Concentration	2 mg Dose	4 mg dose	8 mg dose	12 mg dose
5 mg	1 mL	5 mg/mL	0.4 mL (40 U)	0.8 mL (80 U)	—	—
10 mg	2 mL	5 mg/mL	0.4 mL (40 U)	0.8 mL (80 U)	1.6 mL (160 U)*	—
10 mg	1 mL	10 mg/mL	0.2 mL (20 U)	0.4 mL (40 U)	0.8 mL (80 U)	1.2 mL (120 U)*
20 mg	2 mL	10 mg/mL	0.2 mL (20 U)	0.4 mL (40 U)	0.8 mL (80 U)	1.2 mL (120 U)*

CJC-1295 (No DAC) Reconstitution

Vial size	BAC water added	Concentration	100 mcg dose	200 mcg dose	300 mcg dose
2 mg	1 mL	2,000 mcg/mL	0.05 mL (5 U)	0.10 mL (10 U)	0.15 mL (15 U)
5 mg	2 mL	2,500 mcg/mL	0.04 mL (4 U)	0.08 mL (8 U)	0.12 mL (12 U)
5 mg	2.5 mL	2,000 mcg/mL	0.05 mL (5 U)	0.10 mL (10 U)	0.15 mL (15 U)

Retatrutide Reconstitution

Vial size	BAC water added	Concentration	2 mg	4 mg	6 mg	9 mg	12 mg
10 mg	2 mL	5 mg/mL	40 U	80 U	120 U*	180 U*	240 U*
10 mg	1 mL	10 mg/mL	20 U	40 U	60 U	90 U	120 U*

CJC-1295 + Ipamorelin Combo Vial Reconstitution

Vial size	BAC water added	Concentration (per peptide)	100 mcg of each	200 mcg of each	300 mcg of each
5 mg + 5 mg (10 mg total)	2 mL	2,500 mcg/mL each	4 U (0.04 mL)	8 U (0.08 mL)	12 U (0.12 mL)
5 mg + 5 mg	2.5 mL	2,000 mcg/mL each	5 U (0.05 mL)	10 U (0.10 mL)	15 U (0.15 mL)
2 mg + 2 mg	2 mL	1,000 mcg/mL each	10 U (0.10 mL)	20 U (0.20 mL)	30 U (0.30 mL)

Advanced Recomp Stack vs CagriSema vs Retatrutide Solo vs Reta + MOTS-c

Feature	Advanced Recomp Stack	CagriSema	Retatrutide Solo	Reta + MOTS-c
Components	Retatrutide + CJC-1295 (No DAC) + Ipamorelin	Cagrilintide + Semaglutide	Retatrutide only	Reta + MOTS-c
Receptor targets	GLP-1 + GIP + Glucagon + GHRH + Ghrelin	GLP-1 + Amylin	GLP-1 + GIP + glucagon	GLP-1 + GIP + Glucagon + mitochondrial
GH-axis support	Yes	No	No	No
Peak weight loss	~29% from retatrutide + theoretical lean preservation	~22-24% Phase 3	~29% Phase 3	~29% from reta; mitochondrial support add
Lean mass preservation	Enhanced via GH + IGF-1	Some amylin signal	Limited - deficit risk remains	Limited
Injection burden	1 weekly + daily CJC/Ipa	1 weekly combined	1 weekly	1 weekly + 2-3x weekly MOTS-c
Complexity	High (3 compounds, 3 vials)	Low (single combo)	Low (single)	Moderate
Cost	High	Moderate	Moderate	Moderate-high
Evidence level	Phase 3 (reta) + PK (CJC/Ipa); no stack trial	Phase 3 combination data	Phase 3 monotherapy data	Phase 3 (reta); preclinical for MOTS-c

Storage and handling

The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.

Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
Cloudy solution, with particles or a color change: discard. There is no recovery.

Lab tests and monitoring

This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.

Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.

Evidence limits

What these numbers are and what they are not. The values above were preserved exactly as they appear in the source, without reinterpretation. What the source describes as community practice is marked as such in the tables; what came from a published trial is too. A dose repeated by many people does not become a validated dose by repetition.

Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.

← Back to all compounds